Talus Bio
YC S21Seattle, US · Founded 2020 · 16 employees · 4 known investors
Talus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Founders & leadership· Y Combinator alumni (S21)
Investors · 4
In the news
- Talus Bioscience: Drug Discovery Company Raises $11.2 Million (Seed+)pulse2.com · 2024
- Talus Bio tacks on $11M to target hard-to-reach transcription factorsfiercebiotech.com · 2024
- Talus Bioscience lands $4.3M in grant funding for drug discovery platform – GeekWiregeekwire.com · 2023
- Talus Announces Close of Seed Funding Round and Hires New COO | Talus Bio - Biotechnology & Drug Discoverytalus.bio · 2022
- Inspired by scientist CEOs, Seattle startup lands $9.75M to build up drug discovery platform – GeekWiregeekwire.com · 2022
- To turn off disease-causing genes, Talus Bio wants to knock proteins off of DNA | FierceBiotechfiercebiotech.com · 2021